title: Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.
abstract: The effect of bezafibrate, at doses of 200 mg three times weekly throughout a period of 10 weeks, on lipoprotein (a) and triglyceride-rich lipoproteins including intermediate-density lipoproteins (IDL) has been studied in 12 patients with chronic renal failure receiving haemodialysis. No side-effects were observed, and serum creatine phosphate kinase values remained within normal limits throughout the duration of the study. Serum cholesterol, triglycerides and apoprotein (apo) B significantly decreased after bezafibrate, whereas apo A-I increased significantly. Serum lipoprotein (a) decreased after bezafibrate, although differences reached no statistical significance. The very-low-density lipoproteins (VLDL) cholesterol and the VLDL triglycerides decreased from 0.93 +/- 0.45 mmol/l (Mean +/- SD) to 0.54 +/- 0.27 mmol/l (P less than 0.05) and from 1.50 +/- 0.58 mmol/l to 0.91 +/- 0.35 mmol/l (P less than 0.01) respectively. The IDL cholesterol and IDL triglycerides decreased from 0.44 +/- 0.35 mmol/l to 0.20 +/- 0.18 mmol/l (P = NS) and from 0.46 +/- 0.35 mmol/l to 0.17 +/- 0.12 mmol/l (P less than 0.05) respectively. These data, with a substantial improvement of the lipoprotein profile in patients with chronic renal failure on haemodialysis after treatment with bezafibrate, suggest a decrease in the coronary heart disease risk.
authors.affiliation: Department of Nephrology, Quinta La Salut l'Aliança, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Pelegrí
authors.forename: R
authors.initials: R
authors.lastname: Romero
authors.forename: M
authors.initials: M
authors.lastname: Sentí
authors.forename: X
authors.initials: X
authors.lastname: Nogués
authors.forename: J
authors.initials: J
authors.lastname: Pedro-Botet
authors.forename: J
authors.initials: J
authors.lastname: Rubiés-Prat
mesh_terms: D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000494:pharmacology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D053419:Lipoproteins, IDL; D008875:Middle Aged; D006435:Renal Dialysis; D014280:Triglycerides / Q000097:blood*
chemical_list: D008074:Lipoproteins; D053419:Lipoproteins, IDL; D014280:Triglycerides; D001629:Bezafibrate